HeartSciences Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
2analysts covering
FY EPS (est.)
-$2.83next fiscal year
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly3.4MTarget: Sufficient capital to fund commercial launch and operations
Shareholders' Equity Quarterly2.7MTarget: Above $2,500,000 (Nasdaq minimum requirement)
Granted Patents Annually45.0Target: Continuous expansion of global IP portfolio
Watch Items
- FDA 510(k) Clearance for MyoVista wavECG DeviceTrigger: FDA decision on the December 2025 submissionAction: Initiate commercial-scale operations and sales launch in the U.S. upon clearance.
- FDA 510(k) Submission for Low Ejection Fraction AlgorithmTrigger: Submission target in the first half of calendar 2026Action: Monitor regulatory progress and prepare marketing materials for the MyoVista Insights platform.
- SaaS Revenue Generation and Reference-Site GrowthTrigger: Initial SaaS revenues and deployment across Cibolo Health NetworkAction: Scale up customer success and technical integration teams to support hospital deployments.
Research as of 20 Jun 2026